

From: Lane, Cliff (NIH/NIAID) [E] [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=2D7E368A3137473BBCE161547A82F2DE-CLANE]
Sent: 1/31/2020 6:54:01 PM
To: Grace, Beth (NIH/NIAID) [C] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=c75f1e9e678842258cf6472505f68cd8-bgrace]; Engel, Theresa (NIH) [C] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=e86305ea82754e65b67a63591ed867ba-engelt]; McNay, Laura (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=d089e838a3824b60b91b6c394fedd335-lmcnay]
CC: Baseler, Beth (NIH) [C] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=2363525c118a468b9e8f5f61707c63f5-bbaseler]; Lambert, Laurie (NIH) [C] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a2e9e8510a5e40b991a7067ee8f10eb5-lalambert]
Subject: Re: Task Order 15 - Coronavirus Primers/Reagents

+Dr. Lau

Please be sure to include Dr. Lau on any emails related to INA-RESPOND.

Thanks,

Cliff

On Jan 31, 2020, at 12:10 PM, Lane, Cliff (NIH/NIAID) [E] (b)(6) wrote:

(b)(5)

From: Beth Grace (b)(6)
Date: Thursday, January 30, 2020 at 9:43 AM
To: "Engel, Theresa (NIH) [C]" (b)(6), "Lane, Cliff (NIH/NIAID) [E]" (b)(6), Laura McNay (b)(6)
Cc: "Baseler, Beth (NIH) [C]" (b)(6), Laurie Lambert (b)(6)
Subject: RE: Task Order 15 - Coronavirus Primers/Reagents

(b)(5)

Beth Grace [Contractor]
Division of Clinical Research | National Institute of Allergy and Infectious Diseases National Institutes of Health | Department of Health and Human Services

5601 Fishers Lane, Room 5C31 | Rockville, MD 20852
Tel: (b)(6) | email: (b)(6)

Disclaimer: The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

CLAN0000009407

From: Engel, Theresa (NIH) [C] (b)(6)
Sent: Thursday, January 30, 2020 8:10 AM
To: Lane, Cliff (NIH/NIAID) [E] (b)(6); McNay, Laura (NIH/NIAID) [E] (b)(6); Grace, Beth (NIH/NIAID) [C] (b)(6)
Cc: Baseler, Beth (NIH) [C] (b)(6); Lambert, Laurie (NIH) [C] (b)(6)
Subject: Task Order 15 - Coronavirus Primers/Reagents

Good morning Dr. Lane, Laura, and Beth,

(b)(5)

Please let us know your thoughts and how you would like for us to proceed.

Kind regards,
Theresa

Theresa M. Engel, M.F.S. [C]
Clinical Project Manager IV
Clinical Monitoring Research Program Directorate (CMRPD)
Frederick National Laboratory
Leidos Biomedical Research, Inc.
Support to NIAID
PO Box B
Frederick, MD 21702
Cell: (b)(6)
Office: (b)(6)
Fax: 301-846-6589
E-mail: (b)(6)

NOTICE: This e-mail and any attachments to it are intended only for the identified recipient. It may contain proprietary or otherwise legally protected information for Leidos Biomedical Research, Inc. Any unauthorized use or disclosure of this communication is strictly prohibited. If you have received this communication in error, please notify the sender and delete or otherwise destroy the e-mail and all attachments immediately.

From: Lane, Cliff (NIH/NIAID) [E] [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=2D7E368A3137473BBCE161547A82F2DE-CLANE]
Sent: 1/24/2020 12:03:11 AM
To: Higgs, Elizabeth (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0601ca55a82841aba16353b96cff8ca9-ehiggs]
Subject: Re: ACE2 receptor usage 2019-NCov

Thanks – can you send me the most recent version of the protocol?

From: "Higgs, Elizabeth (NIH/NIAID) [E]" (b)(6)
Date: Thursday, January 23, 2020 at 6:11 PM
To: "Lane, Cliff (NIH/NIAID) [E]" (b)(6)
Subject: Re: ACE2 receptor usage 2019-NCov

Thanks for asking. There are issues but not sure any of the issues below are raised to his level:

- (b)(5)
-
-
-
-

Elizabeth S. Higgs, MD, DTMH, MIA
Global Health Science Advisor
Division of Clinical Research
National Institute of Allergy and Infectious Diseases
NIH, HHS, USG

(b)(6)
Skype: (b)(6)
Cell: (b)(6)

On 1/23/20, 12:02 PM, "Lane, Cliff (NIH/NIAID) [E]" (b)(6) wrote:

Thanks very much.

I am meeting with Muyembe, Placide and Olivier tomorrow. Is there anything related to Palm 2 you would like me to try and address?

Cliff

> On Jan 23, 2020, at 5:19 PM, Higgs, Elizabeth (NIH/NIAID) [E] (b)(6) wrote:
>
> Cliff,
> So the NIAID Preparedness and Response WG met yesterday which was a good update on all the activities. NIAID draft research agenda attached. CRF looks about 2% though denominator unclear. Modeling paper yesterday based on exported cases suggested there were 400K cases in Wuhan. So really not sure.
>

Page 054 of 162

Withheld pursuant to exemption

(b)(5)

of the Freedom of Information and Privacy Act

(b)(5)



>

>

> From: "Munster, Vincent (NIH/NIAID) [E]" (b)(6)

> Date: Wednesday, January 22, 2020 at 5:48 PM

> To: "Bushar, Nicholas (NIH/NIAID) [E]" (b)(6) "Cassetti, Cristina (NIH/NIAID) [E]"

(b)(6), "Marston, Hilary (NIH/NIAID) [E]" (b)(6) "Pierson, Theodore (NIH/NIAID) [E]" (b)(6)

(b)(6) "Read, Sarah (NIH/NIAID) [E]" (b)(6) "Morabito, Kaitlyn (NIH/VRC) [E]"

(b)(6), "Bok, Karin (NIH/VRC) [E]" (b)(6) "Leitner, Wolfgang (NIH/NIAID) [E]"

(b)(6) "Lapham, Cheryl (NIH/NIAID) [E]" (b)(6) "Stumpo, Dante (NIH/NIAID) [E]"

(b)(6) "Dominique, Joyelle (NIH/NIAID) [E]" (b)(6) "Bryant, Paula

(NIH/NIAID) [E]" (b)(6) "Johnson, Martin S. (NIH/NIAID) [E]" (b)(6) "Graham,

Barney (NIH/VRC) [E]" (b)(6) "Schneider, Johanna (NIH/NIAID) [E]" (b)(6)

"Derocco, Amanda (NIH/NIAID) [E]" (b)(6) "Patterson, Jean (NIH/NIAID) [E]"

(b)(6) Gray Handley (b)(6), "Deckhut, Alison (NIH/NIAID) [E]"

, Nancy Touchette (b)(6), "Lerner, Andrea (NIH/NIAID) [E]"

Young, Monique (NIH/VRC) [E]" (b)(6) "Stemmy, Erik (NIH/NIAID) [E]"

(b)(6), "Corbett, Kizzmekia (NIH/VRC) [E]" (b)(6) "Yang, Linda (NIH/NIAID) [E]"

(b)(6) Schmaljohn, Connie (NIH/NIAID) [E]"

> Cc: "Post, Diane (NIH/NIAID) [E]" (b)(6) "Embry, Alan (NIH/NIAID) [E]" (b)(6)

"Rosa, William (NIH/NIAID) [E]" (b)(6) "Lu, Tami (NIH/NIAID) [E]" (b)(6) "Bernabe, Gayle

(NIH/NIAID) [E]" (b)(6), "Chen, Ping (NIH/NIAID) [E]" (b)(6), Robert Sorenson

(b)(6) Jennifer Routh (b)(6) "Nason, Martha (NIH/NIAID) [E]"

(b)(6) John Beigel (b)(6)

- > Subject: ACE2 receptor usage 2019-NCov
- >
- > Dear all,
- >
- > For whoever would like to know more about the receptor usage of the novel coronavirus 2019-NCov, this manuscript was submitted to bioXRV today (I think it takes 1-2 days before it becomes online).
- >
- > Its pretty molecular, and initially designed as a high-throughput assessment of receptor binding and cell entry properties of B-coronaviruses to allow assessment of initial zoonotic properties. However, this also allowed us to determine the receptor for the novel virus really quickly (11 days after obtaining sequence info, or 8 days since ordering the synthesized RBD). Obviously, based on the sequence similarity of the RBD /RBM we had good reason to suspect it was an ACE2 binder, but this is the first formal proof (as far as I'm aware).
- >
- > In short, new virus uses ACE2 and not any of the other receptors like DPP4 or APN.
- >
- > Vincent Munster, PhD
- > Chief, Virus Ecology Section
- > Laboratory of Virology
- > Rocky Mountain Laboratories
- > NIAID/NIH
- >
- > <Letko_Munster 2020 biorXiv submission[1].pdf>
- > <Letko_Munster_2019-nCoV receptor[2].pdf>
- > <2020-01-22_NIAID Draft Research Agenda.docx>

From: Lane, Cliff (NIH/NIAID) [E] [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=2D7E368A3137473BBCE161547A82F2DE-CLANE]
Sent: 1/31/2020 6:17:26 PM
To: Schmaljohn, Connie (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=721430c941df46339ecedefa47ac6dca-schmaljohnc]
CC: Coe, Linda (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=e94dadd44bca4dceb1911d7b9e784ae6-lcoe]
Subject: Re: Update - nCoV budget projections/spending 2020

Nothing for now – just be on standby.

From: "Schmaljohn, Connie (NIH/NIAID) [E]" (b)(6)
Date: Friday, January 31, 2020 at 1:05 PM
To: "Lane, Cliff (NIH/NIAID) [E]" (b)(6)
Cc: "Coe, Linda (NIH/NIAID) [E]" (b)(6)
Subject: FW: Update - nCoV budget projections/spending 2020

Hi Cliff,

Do you want us to do anything with this?

Just had a meeting with the whole team about coronavirus thoughts so I think that everyone is up to speed.

Connie

From: Johnson, Martin S. (NIH/NIAID) [E] (b)(6)
Sent: Friday, January 31, 2020 12:08 PM
To: Mascola, John (NIH/VRC) [E] (b)(6); Graham, Barney (NIH/VRC) [E] (b)(6);
Erbelding, Emily (NIH/NIAID) [E] (b)(6); Daucher, Marybeth (NIH/NIAID) [E] (b)(6);
Holland, Steven (NIH/NIAID) [E] (b)(6); Barron, Karyl (NIH/NIAID) [E] (b)(6);
Lane, Cliff (NIH/NIAID) [E] (b)(6); Auchincloss, Hugh (NIH/NIAID) [E] (b)(6);
McNay, Laura (NIH/NIAID) [E] (b)(6); Casseti, Cristina (NIH/NIAID) [E] (b)(6);
Blaney, Joe (NIH/NIAID) [C] (b)(6); Munster, Vincent (NIH/NIAID) [E] (b)(6);
(b)(6) NIAID Coronavirus Response SWAT 2020
<NIAIDCoronavirusResponseSWAT2020@mail.nih.gov>; Lee, Kun-Lin (NIH/NIAID) [E] (b)(6); Law, Kim (NIH/NIAID) [E] (b)(6)
Cc: McGowan, John J. (NIH/NIAID) [E] (b)(6); Harper, Jill (NIH/NIAID) [E] (b)(6);
Crum, Wayne (NIH/NIAID) [E] (b)(6); Marston, Hilary (NIH/NIAID) [E] (b)(6);
Eisinger, Robert (NIH/NIAID) [E] (b)(6); Lerner, Andrea (NIH/NIAID) [E] (b)(6);
McNay, Laura (NIH/NIAID) [E] (b)(6); Wilson, Hope (NIH/VRC) [E] (b)(6); Grace, Beth (NIH/NIAID) [C] (b)(6);
Blaney, Joe (NIH/NIAID) [C] (b)(6); Cooper, Susan (NIH/NIAID) [E] (b)(6);
Abbey, Lillian (NIH/NIAID) [E] (b)(6); Schneider, Johanna (NIH/NIAID) [E] (b)(6);
(b)(6); NIAID OCGR Leg <NIAIDOCGRLeg@mail.nih.gov>
Subject: Update - nCoV budget projections/spending 2020

All,

It is likely that we will receive further requests from the Dept. about our nCoV \$ needs.

To that end I've attached the following template to consolidate those requests and so we can support a supplemental spending package, project out years and keep track of spending.

When asked, please work with the respective budget contact in your Division who will coordinate the submissions to myself , Wayne and Kun.

For now please proceed with your outbreak response activities. If you have an activity you must advance, but feel you do not have sufficient funds available, please get back to myself or Wayne.

Thanks

Martin

(b)(6)

From: Johnson, Martin S. (NIH/NIAID) [E]
Sent: Monday, January 27, 2020 11:27 AM
To: Mascola, John (NIH/VRC) [E] (b)(6); Graham, Barney (NIH/VRC) [E] (b)(6);
Erbelding, Emily (NIH/NIAID) [E] (b)(6); Daucher, Marybeth (NIH/NIAID) [E]
(b)(6); Holland, Steven (NIH/NIAID) [E] (b)(6); Barron, Karyl (NIH/NIAID)
[E] (b)(6); Lane, Cliff (NIH/NIAID) [E] (b)(6); McNay, Laura (NIH/NIAID) [E]
(b)(6); Cassetti, Cristina (NIH/NIAID) [E] (b)(6); Blaney, Joe (NIH/NIAID) [C]
(b)(6); Munster, Vincent (NIH/NIAID) [E] (b)(6); NIAID Coronavirus Response
SWAT 2020 <NIAIDCoronavirusResponseSWAT2020@mail.nih.gov>; Lee, Kun-Lin (NIH/NIAID) [E] (b)(6)
Law, Kim (NIH/NIAID) [E] (b)(6)
Cc: McGowan, John J. (NIH/NIAID) [E] (b)(6); Harper, Jill (NIH/NIAID) [E] (b)(6);
Crum, Wayne (NIH/NIAID) [E] (b)(6); Marston, Hilary (NIH/NIAID) [E] (b)(6);
Eisinger, Robert (NIH/NIAID) [E] (b)(6); Lerner, Andrea (NIH/NIAID) [E] (b)(6)
NIAID OCGR Leg <NIAIDOCGRLeg@mail.nih.gov>
Subject: RE: nCoV budget projections/spending 2020

Heads up - OMB and HHS will likely request "spending information" and we have created the attached template to respond to that request.

At this time no action is required on your part.

We will let you know as soon as we are contacted by OMB and or HHS.

Thank You in Advance

Martin

I also have summarized your proposals from last Friday and have that information in a separate -similar format. That information is only for internal NIAID purposes. The main reason is that NIH, HHS and OMB must be in the loop before we spout off about needing additional funds. If you have a compelling reason to discuss that data please call.

From: Johnson, Martin S. (NIH/NIAID) [E]

Sent: Friday, January 24, 2020 8:50 AM

To: Mascola, John (NIH/VRC) [E] (b)(6); Graham, Barney (NIH/VRC) [E] (b)(6)

Erbelding, Emily (NIH/NIAID) [E] (b)(6); Daucher, Marybeth (NIH/NIAID) [E]

(b)(6) Holland, Steven (NIH/NIAID) [E] (b)(6); Barron, Karyl (NIH/NIAID)

[E] (b)(6) Lane, Cliff (NIH/NIAID) [E] (b)(6); McNay, Laura (NIH/NIAID) [E]

(b)(6) Cassetti, Cristina (NIH/NIAID) [E] (b)(6); Blaney, Joe (NIH/NIAID) [C]

Munster, Vincent (NIH/NIAID) [E] (b)(6)

Cc: McGowan, John J. (NIH/NIAID) [E] (b)(6); Harper, Jill (NIH/NIAID) [E] (b)(6)

Crum, Wayne (NIH/NIAID) [E] (b)(6); Marston, Hilary (NIH/NIAID) [E] (b)(6)

Eisinger, Robert (NIH/NIAID) [E] (b)(6); Lerner, Andrea (NIH/NIAID) [E] (b)(6)

Subject: RE: nCoV budget projections

We need \$ projections as soon as possible for:

- 1) \$ needs for an immediate response

- 2) \$ needs for response should outbreak expand (in US) - should be significantly higher than #1

Please break out by

- mAb development

- mAb preclinical/Phase I evaluation

- Phase IIb

- Other (assays, animal models, epi)

Please call if you have any questions:

(b)(6)

Thanks

Martin

From: Fauci, Anthony (NIH/NIAID) [E] (b)(6)

Sent: Friday, January 24, 2020 6:28 AM

To: Johnson, Martin S. (NIH/NIAID) [E] (b)(6); McGowan, John J. (NIH/NIAID) [E]

(b)(6); Mascola, John (NIH/VRC) [E] (b)(6); Erbelding, Emily (NIH/NIAID) [E]

(b)(6) McGowan, John J. (NIH/NIAID) [E] (b)(6); Harper, Jill (NIH/NIAID) [E]

Subject: nCoV budget projections

I have an emergency meeting at the White House today and they will ask about budget projections. The meeting is at 1:00 PM, and so we need to have a ballpark number.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b)(6)
FAX: (301) 496-4409
E-mail: (b)(6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Lane, Cliff (NIH/NIAID) [E] [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=2D7E368A3137473BBCE161547A82F2DE-CLANE]
Sent: 1/27/2020 8:36:57 PM
To: Chertow, Daniel (NIH/CC/CCMD) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=90edfb54493c44be982e57addb488927-chertowd]
CC: Schmaljohn, Connie (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=721430c941df46339ecedefa47ac6dca-schmaljohnc]
Subject: Re: Best regards from Zagreb and some coronavirus questions

There are no supplemental funds at this time although that may change.

On Jan 27, 2020, at 8:19 PM, Chertow, Daniel (NIH/CC/CCMD) [E] (b)(6) wrote:

Dear Cliff,

(b)(5)

Thank you.

Sincerely,

Dan

From: "Schmaljohn, Connie (NIH/NIAID) [E]" (b)(6)
Date: Monday, January 27, 2020 at 7:54 AM
To: "Chertow, Daniel (NIH/CC/CCMD) [E]" (b)(6)
Subject: FW: Best regards from Zagreb and some coronavirus questions

Hi Dan,

Please see message below from a colleague in Zagreb. I haven't seen any specific guidelines, but if there are, you probably have.

With regard to work on nCoV, Lisa, Mike and I have been in calls both with Hilary Marston's office (who is coordinating all of the NIAID efforts) and with WHO. Right now, there is no virus isolate available for study. In addition, all NIAID research needs to come from internal funds. (b)(5)

(b)(5)

Cliff gets back on Wednesday and I have this as one of the topics I need to address with him. I am free most of today if you want to discuss

Connie

Connie Schmaljohn, Ph.D.
Director
NIAID Integrated Research Facility
Phone: (b)(6)
E-Mail: [redacted]

----- Forwarded message -----

From: **Alemka Markotic** (b)(6)
Date: Sun, Jan 26, 2020 at 3:04 PM
Subject: Best regards from Zagreb and some coronavirus questions
To: Connie Russell (b)(6)

Dear Connie,

I hope you are happy in your new position and things are going well.
I appreciate some more information or advices regarding 2019-n-coronavirus if you have it.

We are also trying to prepare the best we can for potential cases to come.

For the time being, we plan to use disposable overcoat, goggles and masks (FFP3) in the admissions unit to protect doctors and nurses. In the isolation department we would use suits, goggles, FFP3 masks, and in intensive respirators with HEPA filters. Do you have any other suggestions?
Do you have any additional information about the treatment for now? Are the Chinese doctors only administer symptomatic therapy, or do they provide any of the antiviral drugs?
Is there reliable information on the possible transmission of the virus during incubation?
Any good advice or information would be welcome.

Thank you very much in advance and best regards,

Alemka

Professor Alemka Markotic, MD, PhD
Director
University Hospital for Infectious Diseases

--

Professor Alemka Markotic, MD, PhD

Head of The Research Department, University Hospital for Infectious Diseases "Dr. Fran Mihaljevic"

Mirogojska 8, 10000 Zagreb, Croatia

Tel/fax: (b)(6)

Mobile phone: (b)(6)

E-mail: (b)(6) (b)(6)

From: Lane, Cliff (NIH/NIAID) [E] [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=2D7E368A3137473BBCE161547A82F2DE-CLANE]
Sent: 1/20/2020 9:35:45 PM
To: Sean Emery (b)(6)
Subject: Re: Wuhan

WHO is very actively coordinating activities. CEPI is working with them to create a landscape of research activities. As you say the situation seems to be very much in flux with many unknowns.

On 1/20/20, 3:16 PM, "Sean Emery" (b)(6) wrote:

Still watch and wait on 2019 nCoV infection? The numbers are concerning and likely wilfully undercooked.

Cheers

Sean

Sent from my iPad

From: Lane, Cliff (NIH/NIAID) [E] [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=2D7E368A3137473BBCE161547A82F2DE-CLANE]
Sent: 1/28/2020 2:05:22 PM
To: Fallah, Mosoka (ACF - Liberia) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=16edcb6165ae4bb4af44aa2d7e36dd8e-mfallah1969]
CC: Williams, Desmond E. (CDC/DDPHSIS/CGH/DGHP) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=d3565023855b48b689661c9243c5ac71-zhx0.CDC]; Damon, Inger K. (CDC/DDID/NCEZID/DHCPP) [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0142deba24f42fa8228ccfde3c5efb0-IAD7]
Subject: Re: Please help us with Primer and Probe for the novel Coronavirus

I have heard that CDC and WHO are providing technical support to labs.

I have copied Desmond and Inger in the hope they can put you in contact with the correct person at CDC.

Cliff

> On Jan 28, 2020, at 3:55 PM, Mosoka Fallah (b)(6) wrote:
>
> Good morning Cliff
> We are preparing for the eventuality of an imported case of Coronavirus in Liberia given that we have lots of Chinese coming in Liberia and many Liberians travel to China for business and education.
> Our record indicated that from December to current, there were 313 Chinese that came to Liberia.
> Hence, we want to prepare our laboratory folks with the appropriate primers and probes since we have the PCR platform.
> Is there anyway you could help us get it or link us to a resource to get them.
> Mosoka
>
> Mosoka P. Fallah, PhD, MPH, MA
> Acting Director General
> National Public Health Institute of Liberia (NPHIL)

From: Lane, Cliff (NIH/NIAID) [E] [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=2D7E368A3137473BBCE161547A82F2DE-CLANE]
Sent: 1/27/2020 8:49:43 PM
To: STAG IH Secretariat [stag-ih-secretariat@who.int]
Subject: Re: !!STAG_IH!! 2019-nCoV update call

Nikki,

I am sorry I will be in transit at that time.

Cliff

On Jan 27, 2020, at 6:27 PM, STAG IH Secretariat <stag-ih-secretariat@who.int> wrote:

Dear STAG-IH,

We will need time to incorporate overwhelming volume of information coming in. To this effect, we propose to hold the next STAG-IH nCoV update call on **Wednesday, 29 January, 1pm Geneva time.**

More to follow.

Secretariat

From: Lane, Cliff (NIH/NIAID) [E] [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=2D7E368A3137473BBCE161547A82F2DE-CLANE]
Sent: 1/27/2020 8:51:56 PM
To: Marston, Hilary (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ab30660917b942ffba9ae95d631116f3-marstonhd]
Subject: Fwd: 2019-nCoV blog post for Science Speaks

Hilary,

Please review the note below from IDSA and feel free to respond directly to Jaclyn, copy to me.

Thanks,

Cliff

Begin forwarded message:

From: "Levy, Jaclyn" <jlevy@idsociety.org>
Date: January 27, 2020 at 6:13:27 PM GMT+2
To: "Lane, MD, H. Clifford" <(b)(6)>
Subject: 2019-nCoV blog post for Science Speaks

Dear Dr. Lane,

IDSA has been coordinating press statements, news releases, social media, and resources for 2019-nCoV. In an effort to provide continued relevant updates are asking members of each relevant committee to provide additional details via our blog, *Science Speaks*. The idea is to cite the current situation as it applies to the existing asks and priorities of IDSA's committees (vs. a big picture analysis).

Are there 2019-nCoV initiatives NIAID/NIH is spearheading or considering, or challenges/progress/needs, that we can report on behalf of the Research Committee? An NIH guest blog post would certainly be wonderful, but if sharing bullet points or more general information is a more feasible option our Communications folks are happy to fashion background into a written piece. We'd like to keep members as updated as possible while respecting the many competing demands on your time and hopefully simplify the process.

We greatly appreciate anything you might be able to share and happy to discuss further anytime.

Best,
Jaclyn

JACLYN LEVY, MS
Director, Science and Research Policy
Infectious Diseases Society of America
w. (703) 299-1216 | c. (b)(6)
<https://www.idsociety.org> | [Facebook](#) | [Twitter](#)

From: Lane, Cliff (NIH/NIAID) [E] [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=2D7E368A3137473BBCE161547A82F2DE-CLANE]
Sent: 1/27/2020 9:07:09 PM
To: Higgs, Elizabeth (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0601ca55a82841aba16353b96cff8ca9-ehiggs]
Subject: Re: STAT: Morning Rounds -- The latest on the new coronavirus, how caregivers feel, & reducing prostate cancer disparities

Confirmed. We can offer to hell but they should have the lead.

On Jan 27, 2020, at 3:20 PM, Higgs, Elizabeth (NIH/NIAID) [E] (b)(6) wrote:

Cliff

I'm sure you are fully up to date by this point.

WHO R&D BP call this am. John Beigel joined. Looking for volunteers for a master global protocol.

Probably 50 people on the call so not very functional. Can you confirm that DMID has the lead on a therapeutics protocol have asked Hilary as well. CFR 3.2

Thanks

Libby



From: Greg Folkers (b)(6)

Date: Monday, January 27, 2020 at 7:02 AM

Subject: STAT: Morning Rounds -- The latest on the new coronavirus, how caregivers feel, & reducing prostate cancer disparities

Sponsored by





**Containing new coronavirus may not be feasible,
experts say**

The new coronavirus emerging from China has sickened more than 2,700 and killed 80, and some infectious disease experts are warning that it may no longer be possible to contain. The virus has already spread to at least 14 countries and territories outside of mainland China, which have reported nearly 60 cases in total. The U.S. reported three new cases over the weekend, bringing its total to five — two people in southern California and one in Arizona, all three of whom had recently traveled to Wuhan. If the virus' circulation can't be stopped in China, experts say there could potentially be sustained spread around the world. “The more we learn about it, the greater the possibility is that transmission will not be able to be controlled with public health measures,” says Dr. Allison McGeer, a Toronto-based infectious disease specialist, who also cautions that the true severity of the outbreak isn't known at this point.

Caregivers feel listened to by health workers, but are rarely asked about needing help

While most family and unpaid caregivers looking after older adults feel listened to when talking with the adults' health care provider, a small new survey finds that few are asked about needing assistance. Here's more:

- **Interaction with health providers:** The vast majority of those surveyed said they always or usually feel heard by the older adults' health providers. At the same time, fewer than half of caregivers interact with clinicians.
- **Assistance:** Almost half of caregivers said they were never asked about needing help tending to the person under their

care, while about 20% said they were always asked. Those who interacted with health workers were more likely to be asked about needing assistance with caregiving.

- **Dementia care:** Those assisting adults with dementia were more likely to report being listened to, and asked about needing help and whether they understood the medications they were handling.

Equal access to care could help reduce prostate cancer disparities


The results of a new study find that having ready access to the same quality of care could reduce prostate cancer disparities between African American and white men. Looking at data from more than 60,000 African American and white men who sought prostate cancer care at the VA — an equal-access health system — scientists found that, compared to the general population, African American men were not first diagnosed with more advanced stages of the disease, nor did they have significant delays in receiving a diagnosis or care. The 10-year mortality rate among African American men was slightly lower — at 4.4% — than the 5.1% rate among white men. Nationally, Black men have a higher chance of dying from prostate cancer than white men, and the authors suggest the difference in the study could be because veterans have equal access to care of the same quality.

SPONSOR CONTENT BY VITUITY

Innovate Now: A 2020 Guide for Hospital Leaders

Innovation is not dependent on a national footprint or a deep capital well. Gain insights from leading experts in care delivery, along with three case studies showcasing cost-effective care models that transform hospitals. One study highlighted an ED Revisit Reduction Program that saved a hospital over \$500,000 in unfunded ED and observation care. Learn more [here](#).

Inside STAT: 'Gurus of sperm': Ohana Biosciences takes a different approach to fertility



(MOLLY FERGUSON FOR STAT)

IVF “add-ons” — supplementary procedures that claim a more successful shot at a pregnancy, but are not necessary — are taking off, and Cambridge, Mass.-based Ohana Biosciences is getting in the game. The company’s focus is on sperm: improving its quality and motility to improve IVF or perhaps helping even people without fertility issues have healthier pregnancies or children. Ohana’s work is in early stages — its first clinical trial testing the company’s

technology began last September. Still, experts say that it's unclear whether improving the health of sperm has any long-term effects on the health of a pregnancy or a child, skepticism that the self-proclaimed "gurus of sperm" at Ohana will have to work to overcome. STAT Plus subscribers can read more from STAT's Kate Sheridan [here](#).

Trump is first sitting president to attend March for Life

President Trump on Friday became the first sitting American president to speak at the annual anti-abortion March for Life rally, which he called a "profound honor." In the past, Trump has described himself as "pro-choice," but since launching his presidential campaign and taking office, he has appointed anti-abortion judges to courts across the country, and reinstated — and expanded — the Mexico City policy that withholds international aid for abortion services. He referred to both these steps in his speech, but also made false claims about Democrats' support for the procedure "up until the moment of birth."

At the same time, the administration on Friday warned California that its law requiring all health insurers to cover abortion was violating federal law. The administration threatened to withhold Medicaid funding to the state — more than \$50 billion — if it did not comply.

Q&A: Behind the movie deal on one reporter's investigation into Purdue and the Sacklers

Los Angeles-based 101 Studios recently announced its plan to finance and distribute a feature film about investigative reporter David Armstrong — formerly of STAT, and now at ProPublica — and how he has worked for years to uncover how the Sackler family and Purdue Pharma contributed to the opioid crisis through aggressive marketing of its drug OxyContin. I spoke with Gita Pullapilly and Aron Gaudet, the screenwriters behind this new project, to learn more.

What inspired you to pursue this story?

Pullapilly: We had stumbled across the news articles a few years ago, and we were so impressed by the storytelling and the writing. These stories are just pretty incredible — the investigative reporting is fascinating, but also so detailed and specific. We both come from journalism, and it's hard to impress journalists, but we were so taken by it.

What are you hoping to impart?

Gaudet: I don't know if we'll ever tackle a more important story because of how many lives [the opioid crisis] has affected. It's so hard to keep people's attention — they may read an article here and there, but if we can get them into a movie theater for two hours and really lay out the story in a very linear, cohesive way for them to understand [because] it's really important for everyone to know the truth.

Pullapilly: It's inspiring to us to see what it takes to figure out the truth — and it can take years to do that.

What to read around the web today

- The coronavirus in China could threaten pharma's ingredient source. *STAT*
- Call for FDA to withdraw preterm birth drug divides doctors and insurers. *Kaiser Health News*
- An ethical future for brain organoids takes shape. *Quanta*
- These 10 startups acquired by Alphabet reveal a health care play centered on surveillance. *STAT Plus*
- The selling of CTE: How the 'Concussion' doctor built a career on distorted science. *The Washington Post*

Thanks for reading! More tomorrow,



HAVE A NEWS TIP OR COMMENT?

[EMAIL ME](#)

<image001.png>

Monday, January 27, 2020



▪
▪

HAVE A NEWS TIP OR COMMENT?

EMAIL ME

From: Lane, Cliff (NIH/NIAID) [E] [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=2D7E368A3137473BBCE161547A82F2DE-CLANE]
Sent: 1/27/2020 9:25:44 PM
To: Higgs, Elizabeth (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0601ca55a82841aba16353b96cff8ca9-ehiggs]
Subject: Re: STAT: Morning Rounds -- The latest on the new coronavirus, how caregivers feel, & reducing prostate cancer disparities

Make that "help"!

On Jan 27, 2020, at 11:18 PM, Higgs, Elizabeth (NIH/NIAID) [E] [redacted] wrote:

Thanks.

Elizabeth S. Higgs, MD, DTMH, MIA
Global Health Science Advisor
Division of Clinical Research
National Institute of Allergy and Infectious Diseases
NIH, HHS, USG

[redacted]
Skype: [redacted]
Cell: [redacted]

From: Cliff Lane [redacted]
Date: Monday, January 27, 2020 at 4:07 PM
To: [redacted]
Subject: Re: STAT: Morning Rounds -- The latest on the new coronavirus, how caregivers feel, & reducing prostate cancer disparities



Confirmed. We can offer to hell but they should have the lead.

On Jan 27, 2020, at 3:20 PM, Higgs, Elizabeth (NIH/NIAID) [E] [redacted] wrote:

Cliff
I'm sure you are fully up to date by this point.
WHO R&D BP call this am. John Beigel joined. Looking for volunteers for a master global protocol. Probably 50 people on the call so not very functional. Can you confirm that DMID has the lead on a therapeutics protocol have asked Hilary as well. CFR 3.2
Thanks
Libby

From: Greg Folkers [redacted]
Date: Monday, January 27, 2020 at 7:02 AM
Subject: STAT: Morning Rounds -- The latest on the new coronavirus, how caregivers feel, & reducing prostate cancer disparities

Sponsored by



Containing new coronavirus may not be feasible, experts say

The new coronavirus emerging from China has sickened more than 2,700 and killed 80, and some infectious disease experts are warning that it may no longer be possible to contain. The virus has already spread to at least 14 countries and territories outside of mainland China, which have reported nearly 60 cases in total. The U.S. reported three new cases over the weekend, bringing its total to five — two people in southern California and one in Arizona, all three of whom had recently traveled to Wuhan. If the virus' circulation can't be stopped in China, experts say there could potentially be sustained spread around the world. “The more we learn about it, the greater the possibility is that transmission will not be able to be controlled with public health measures,” says Dr. Allison McGeer, a Toronto-based infectious disease specialist, who also cautions that the true severity of the outbreak isn't known at this point.

Caregivers feel listened to by health workers, but are rarely asked about needing help

While most family and unpaid caregivers looking after older adults feel listened to when talking with the adults' health care provider, a small new survey finds that few are asked about needing assistance. Here's more:

- **Interaction with health providers:** The vast majority of those surveyed said they always or usually feel heard by the older adults' health providers. At the same time, fewer than half of caregivers interact with clinicians.

- **Assistance:** Almost half of caregivers said they were never asked about needing help tending to the person under their care, while about 20% said they were always asked. Those who interacted with health workers were more likely to be asked about needing assistance with caregiving.
- **Dementia care:** Those assisting adults with dementia were more likely to report being listened to, and asked about needing help and whether they understood the medications they were handling.

Equal access to care could help reduce prostate cancer disparities

The results of a new study find that having ready access to the same quality of care could reduce prostate cancer disparities between African American and white men. Looking at data from more than 60,000 African American and white men who sought prostate cancer care at the VA — an equal-access health system — scientists found that, compared to the general population, African American men were not first diagnosed with more advanced stages of the disease, nor did they have significant delays in receiving a diagnosis or care. The 10-year mortality rate among African American men was slightly lower — at 4.4% — than the 5.1% rate among white men. Nationally, Black men have a higher chance of dying from prostate cancer than white men, and the authors suggest the difference in the study could be because veterans have equal access to care of the same quality.

SPONSOR CONTENT BY VITUITY

Innovate Now: A 2020 Guide for Hospital Leaders

Innovation is not dependent on a national footprint or a deep capital well. Gain insights from leading experts in care delivery, along with three case studies showcasing cost-effective care models that transform hospitals. One study highlighted an ED Revisit Reduction Program that saved a hospital over \$500,000 in unfunded ED and observation care. Learn more [here](#).

Inside STAT: 'Gurus of sperm': Ohana Biosciences takes a different approach to fertility



(MOLLY FERGUSON FOR STAT)

IVF “add-ons” — supplementary procedures that claim a more successful shot at a pregnancy, but are not necessary — are taking off, and Cambridge, Mass.-based Ohana Biosciences is getting in the game. The company’s focus is on sperm: improving its quality and motility to improve IVF or perhaps helping even people without fertility issues have healthier pregnancies or children. Ohana’s work

is in early stages — its first clinical trial testing the company’s technology began last September. Still, experts say that it’s unclear whether improving the health of sperm has any long-term effects on the health of a pregnancy or a child, skepticism that the self-proclaimed “gurus of sperm” at Ohana will have to work to overcome. STAT Plus subscribers can read more from STAT’s Kate Sheridan [here](#).

Trump is first sitting president to attend March for Life

President Trump on Friday became the first sitting American president to speak at the annual anti-abortion March for Life rally, which he called a “profound honor.” In the past, Trump has described himself as “pro-choice,” but since launching his presidential campaign and taking office, he has appointed anti-abortion judges to courts across the country, and reinstated — and expanded — the Mexico City policy that withholds international aid for abortion services. He referred to both these steps in his speech, but also made false claims about Democrats’ support for the procedure “up until the moment of birth.”

At the same time, the administration on Friday warned California that its law requiring all health insurers to cover abortion was violating federal law. The administration threatened to withhold Medicaid funding to the state — more than \$50 billion — if it did not comply.

Q&A: Behind the movie deal on one reporter's investigation into Purdue and the Sacklers

Los Angeles-based 101 Studios recently announced its plan to finance and distribute a feature film about investigative reporter David Armstrong — formerly of STAT, and now at ProPublica — and how he has worked for years to uncover how the Sackler family and Purdue Pharma contributed to the opioid crisis through aggressive marketing of its drug OxyContin. I spoke with Gita Pullapilly and Aron Gaudet, the screenwriters behind this new project, to learn more.

What inspired you to pursue this story?

Pullapilly: We had stumbled across the news articles a few years ago, and we were so impressed by the storytelling and the writing. These stories are just pretty incredible — the investigative reporting is fascinating, but also so detailed and specific. We both come from journalism, and it's hard to impress journalists, but we were so taken by it.

What are you hoping to impart?

Gaudet: I don't know if we'll ever tackle a more important story because of how many lives [the opioid crisis] has affected. It's so hard to keep people's attention — they may read an article here and there, but if we can get them into a movie theater for two hours and really lay out the story in a very linear, cohesive way for them to understand [because] it's really important for everyone to know the truth.

Pullapilly: It's inspiring to us to see what it takes to figure out the truth — and it can take years to do that.

What to read around the web today

- The coronavirus in China could threaten pharma's ingredient source. [STAT](#)
- Call for FDA to withdraw preterm birth drug divides doctors and insurers. [Kaiser Health News](#)
- An ethical future for brain organoids takes shape. [Quanta](#)
- These 10 startups acquired by Alphabet reveal a health care play centered on surveillance. [STAT Plus](#)
- The selling of CTE: How the 'Concussion' doctor built a career on distorted science. [The Washington Post](#)

Thanks for reading! More tomorrow,



HAVE A NEWS TIP OR COMMENT?

[EMAIL ME](#)

<image001.png>

Monday, January 27, 2020



▪
▪

From: Lane, Cliff (NIH/NIAID) [E] [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=2D7E368A3137473BBCE161547A82F2DE-CLANE]
Sent: 1/28/2020 2:35:23 PM
To: Wu, Richard (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=bf739675de04d859f5a1337d4e4e9f4-wurl]
Subject: Re: Question about travel and the Coronavirus

I think things will be much clearer in a few weeks and would not make any changes right now. There are many unknowns. You have likely seen the airlines are letting people reschedule current flights to China.

On Jan 28, 2020, at 4:28 PM, Wu, Richard (NIH/NIAID) [E] (b)(6) wrote:

Hi Dr. Lane,

I just wanted to get your opinion on a personal question (b)(6)

(b)(6)

Thanks for your help!

From: Lane, Cliff (NIH/NIAID) [E] [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=2D7E368A3137473BBCE161547A82F2DE-CLANE]
Sent: 1/27/2020 4:10:22 PM
To: Dodd, Lori (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=a2964312396745bcbf1253d1787f5222-doddl]
CC: Sow, Ydrissa (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=17995c0ff0974d2dadd967014417e63e-sowy]
Subject: Re: Laurie Doepel

You should reach out to her. I always take her when possible. She may be obe due to coronavirus.

On Jan 27, 2020, at 4:36 PM, Dodd, Lori (NIH/NIAID) [E] (b)(6) wrote:

Cliff-

As part of an effort to keep Laurie better informed about our work, would it be a good idea to include her at the F2F meeting in Kinshasa in late Feb?

This came from a conversation Drissa and I had.

-Lori

From: Lane, Cliff (NIH/NIAID) [E] [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=2D7E368A3137473BBCE161547A82F2DE-CLANE]
Sent: 1/27/2020 4:16:29 PM
To: McNay, Laura (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=d089e838a3824b60b91b6c394fedd335-lmcnay]
CC: Grace, Beth (NIH/NIAID) [C] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=c75f1e9e678842258cf6472505f68cd8-bgrace]
Subject: Re: Coronavirus Outbreak spending to date

(b)(5)

On Jan 27, 2020, at 4:11 PM, McNay, Laura (NIH/NIAID) [E] (b)(6) wrote:

Thoughts?

From: "Johnson, Martin S. (NIH/NIAID) [E]" (b)(6)
Date: Monday, January 27, 2020 at 9:03 AM
To: Laura McNay (b)(6)
Subject: RE: Coronavirus Outbreak spending to date

Laura,

I take responsibility for that. I did not have a chance to update this between the time he had wanted this and when I had spoken with you.

These are for internal purposes so if DCR does not require the funds we can always use them elsewhere.

(b)(5)

(b)(5)

Will keep you posted.

From: McNay, Laura (NIH/NIAID) [E] (b)(6)
Sent: Friday, January 24, 2020 9:47 PM
To: Johnson, Martin S. (NIH/NIAID) [E] (b)(6)
Subject: Re: Coronavirus Outbreak spending to date

No. I just noticed some figures in our column.

Laura

CLAN000009421

On Jan 24, 2020, at 9:44 PM, Johnson, Martin S. (NIH/NIAID) [E]

(b)(6) wrote:

Laura

I did not receive any figure from DCR. Did you have anything to report ?

Thanks

From: "McNay, Laura (NIH/NIAID) [E]" (b)(6)

Date: Friday, January 24, 2020 at 8:27:31 PM

To: "Johnson, Martin S. (NIH/NIAID) [E]" (b)(6)

Subject: Re: Coronavirus Outbreak spending to date

From where did the DCR numbers come?

Laura

On Jan 24, 2020, at 4:16 PM, Johnson, Martin S. (NIH/NIAID) [E]

(b)(6) wrote:

All,

(b)(5)

Thanks

From: Shapiro, Neil (NIH/OD) [E] (b)(6)

Sent: Friday, January 24, 2020 3:40 PM

To: Johnson, Martin S. (NIH/NIAID) [E] (b)(6)

Shaya, Cecile (NIH/OD) [E] (b)(6); Crum, Wayne

(NIH/NIAID) [E] (b)(6); Marston, Hilary (NIH/NIAID)

[E] (b)(6) Bushar, Nicholas (NIH/NIAID) [E]

(b)(6) >
Cc: Harper, Jill (NIH/NIAID) [E] (b)(6) Myers, Jesse

(NIH/OD) [E] (b)(6)

Subject: RE: Coronavirus Outbreak spending

ASFR clarified that what they need today is any spending that has occurred on coronavirus specific to the outbreak. The question about unmet needs is less time-sensitive.

Neil

From: Shapiro, Neil (NIH/OD) [E]
Sent: Friday, January 24, 2020 3:36 PM
To: Johnson, Martin S. (NIH/NIAID) [E]; Shaya, Cecile (NIH/OD) [E]; Crum, Wayne (NIH/NIAID) [E]; Marston, Hilary (NIH/NIAID) [E]; Bushar, Nicholas (NIH/NIAID) [E]
Cc: Harper, Jill (NIH/NIAID) [E]; Myers, Jesse (NIH/OD) [E]
Subject: RE: Coronavirus Outbreak spending

Martin, we are trying to clarify this request. Do you have what NIAID expects to spend this year from existing resources? ASFR would also like to know if there are any needs not being met with current resources. Perhaps that's what you mean for the ballpark estimate; until we hear otherwise I'd assume that NIAID could be directed to meet those needs and eat the cost.

From: Johnson, Martin S. (NIH/NIAID) [E]
Sent: Friday, January 24, 2020 3:13 PM
To: Shaya, Cecile (NIH/OD) [E]; Crum, Wayne (NIH/NIAID) [E]; Marston, Hilary (NIH/NIAID) [E]; Bushar, Nicholas (NIH/NIAID) [E]
Cc: Harper, Jill (NIH/NIAID) [E]; Shapiro, Neil (NIH/OD) [E]; Myers, Jesse (NIH/OD) [E]
Subject: RE: Coronavirus Outbreak spending

Cecile,

I'll double check with NIAID Leadership, but we have a ballpark estimate for an immediate response that would represent funds over and above our regular appropriation.

Martin

From: Shaya, Cecile (NIH/OD) [E]
Sent: Friday, January 24, 2020 9:59 AM
To: Johnson, Martin S. (NIH/NIAID) [E]; Shaya, Cecile (NIH/OD) [E]; Crum, Wayne (NIH/NIAID) [E]; Marston, Hilary (NIH/NIAID) [E]; Bushar, Nicholas (NIH/NIAID) [E]
Cc: Harper, Jill (NIH/NIAID) [E]; Shapiro, Neil (NIH/OD) [E]; Myers, Jesse (NIH/OD) [E]
Subject: Re: Coronavirus Outbreak spending

Hello Martin - The Department would like to have the information by the end of today. Please provide any information you have on coronavirus. If it needs additional information, we can follow up later.

Thanks,
Cecile

From: "Johnson, Martin S. (NIH/NIAID) [E]" (b)(6)
Date: Thursday, January 23, 2020 at 6:57:39 PM
To: "Shaya, Cecile (NIH/OD) [E]" (b)(6), "Crum, Wayne (NIH/NIAID) [E]" (b)(6), "Marston, Hilary (NIH/NIAID) [E]" (b)(6), "Bushar, Nicholas (NIH/NIAID) [E]" (b)(6)
Cc: "Harper, Jill (NIH/NIAID) [E]" (b)(6), "Shapiro, Neil (NIH/OD) [E]" (b)(6), "Myers, Jesse (NIH/OD) [E]" (b)(6)
Subject: RE: Coronavirus Outbreak spending

Cecile,

Is there anything more specific about this request ?

I would request additional time .

Thanks

From: Shaya, Cecile (NIH/OD) [E] (b)(6)
Sent: Thursday, January 23, 2020 6:42 PM
To: Johnson, Martin S. (NIH/NIAID) [E] (b)(6); Crum, Wayne (NIH/NIAID) [E] (b)(6)
Cc: Harper, Jill (NIH/NIAID) [E] (b)(6); Shapiro, Neil (NIH/OD) [E] (b)(6); Myers, Jesse (NIH/OD) [E] (b)(6)
Subject: Coronavirus Outbreak spending
Importance: High

Hello Martin and Wayne - OMB is requesting spending information on the coronavirus outbreak. Could you please provide by 3 pm tomorrow. If you need more time, please let us know.

Sorry for the rush request.
Cecile

<Corona_1_24_2020_Update_Final.xlsx>

From: Lane, Cliff (NIH/NIAID) [E] [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=2D7E368A3137473BBCE161547A82F2DE-CLANE]
Sent: 1/27/2020 4:20:54 PM
To: Schmaljohn, Connie (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=721430c941df46339ecedefa47ac6dca-schmaljohnc]
CC: Coe, Linda (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=e94dadd44bca4dceb1911d7b9e784ae6-lcoe]
Subject: Re: Wednesday

Looks good. I think we can get through this!

On Jan 27, 2020, at 3:52 PM, Schmaljohn, Connie (NIH/NIAID) [E] (b)(6) wrote:

Hi Cliff,

So as not to blindside you, here is a list of things to discuss when we meet. It is OK if we don't get through all of them. Some are just to update you on what has happened while you were away. Everything is going very well. I love it here.

Items to discuss

1. PMAP:
 - a. Revisions for 9 months vs 12 months
 - b. add CEPI SAC?
 - c. (b)(6)
2. CEPI conference call with Richard/Nicky?
3. Heinz visit February 27-28
4. Chinese coronavirus work at IRF?
5. DARPA project
6. BSL3 lab safety changes for U19 grant work on Alphaviruses
7. My conference call with Heinz and Dave Safronetz about Nigerian LASV
8. Shipment of RML samples to IRF
9. Travel:
 - a. May 5-6 Umea University (travel funding)
 - b. May 11-12 CEPI SAC, Oslo
10. Pathologists at NBACC
11. Gustavo: and sequencing

Thanks
Connie

From: Lane, Cliff (NIH/NIAID) [E] [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=2D7E368A3137473BBCE161547A82F2DE-CLANE]
Sent: 1/20/2020 12:56:58 PM
To: Marston, Hilary (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ab30660917b942ffba9ae95d631116f3-marstonhd]
Subject: Re: GCM call

I have heard that Bill Dowling (now CEPI) is in Geneva to help with the R and D blueprint activities.

On Jan 20, 2020, at 7:36 AM, Marston, Hilary (NIH/NIAID) [E] (b)(6) wrote:

WHO convened a Global Coordination Mechanism of the R&D Blueprint call this morning.

Epidemiology/investigations

- Total cases: 198 cases, 43 severe, 9 critical, 3 deaths
- Thailand – 2nd case is a Chinese person who traveled from Wuhan to Thailand; no clear info about market exposure
- Republic of Korea – traveled from Wuhan and developed symptoms on the 20th of January; detected by thermal screening
- Three confirmed cases outside of Wuhan in China – 2 new in Beijing detected on January 19, 1 in Guangdong
- Three confirmed cases in Japan
- Incubation period appears to be about 7 days (range 0 to 14)
- In Wuhan, environmental sampling studies are being conducted – so far 15 specimens are positive
- Epidemiological investigations ongoing regarding transmission routes (animal-to-human and human-to-human)
- Retroactive and active case finding
- Clinical case form

Diagnostics working group: All initial diagnoses based on sequencing; now PCR assays developed by multiple groups; guidance on laboratory diagnosis placed on WHO website. WHO is working on reference materials to validate tests. To date, no access to virus.

Data sharing

A number of manuscripts are likely to be in the works; ICJME policy states that it is critical that WHO sees data regardless of publication date. There should be pre-publication sharing of manuscripts with WHO.

Sequence sharing is going well – to date 11 Chinese, 2 Thai, 1 Japanese sequences have been shared.

Sample sharing

WHO ready to help with materials transfer agreements for the sharing of viruses. Defining objectives of sample sharing (what is planned with the samples).

Research plans: INSERM plans are under review by the French government. I gave a high-level overview of NIH research priorities.

Vaccines and therapeutics – high-level summary of landscape prepared and being refined. For both vax and tx, WHO envisions a master protocol.

From: Lane, Cliff (NIH/NIAID) [E] [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=2D7E368A3137473BBCE161547A82F2DE-CLANE]
Sent: 1/30/2020 11:51:10 AM
To: Carver, Trea (NIH) [C] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=ac05f976df484ed69022b8663cd448d3-carverkr]
Subject: Fwd: GIH weekly publication review No.3 - 2020

Hardcopy - thanks.

Dear all,

(b)(5)

Best wishes,

Oh Myoung-don, M.D.
Professor,
Department of Internal Medicine
Seoul National University College of Medicine
Seoul National University Hospital
101 Daehak-ro, Jongno-gu, Seoul, 03080, South Korea
TEL: (b)(6) FAX: 82-2-762-9662
e-mail: (b)(6)

----- 원본 메일 -----

Dear all,

(b)(5)

Thanks from me also, Myoung-don for sharing your manuscript.

CLAN0000009430

Best,

Johan

(b)(5)

DLH

Dear David and all,
I'd like to share our experience from the first imported case into Korea. This is an excerpt from our case report (not published yet)

(b)(4)

Regards,

Oh Myoung-don, M.D.
Professor,
Department of Internal Medicine
Seoul National University College of Medicine
Seoul National University Hospital
101 Daehak-ro, Jongno-gu, Seoul, 03080, South Korea
TEL: (b)(6) FAX: 82-2-762-9662
e-mail: (b)(6)

----- 원본 메일 -----

From: Lane, Cliff (NIH/NIAID) [E] [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=2D7E368A3137473BBCE161547A82F2DE-CLANE]
Sent: 1/29/2020 6:45:06 PM
To: Claudia Christian (b)(6)
CC: McNay, Laura (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=d089e838a3824b60b91b6c394fedd335-lmcnay]
Subject: Re: Checking in- Wuhan Coronavirus

Claudia,

Thanks very much for reaching out. If you could provide a bit more detail on what you would see as the best situated sites (infrastructure-esp personnel; politics; case load) it would be of interest.

Thanks,

Cliff

On Jan 29, 2020, at 7:32 PM, Claudia Christian (b)(6) wrote:

Dear Dr. Lane,

I imagine 2020 is off to a busy start for you and your team with the ongoing network activities, upcoming PREVAIL events and the recent coronavirus events to name a few.

We are tracking the coronavirus news closely and are always ready to assist in any way we can. I wanted to send you a note to remind you of the amazing network we set up for TB clinical trials in China with NIH funds that is now in excess of 20 sites including general hospitals and ID units. We know that some of those sites are seeing coronavirus patients now. We also would be able to mobilize quickly in neighboring countries that are also seeing cases (e.g. Thailand, Vietnam, Cambodia, etc.).

<image002.png><image010.png>

Please let us know if we can provide any additional information and support to address the growing crisis.

Thanks for taking the time to look at one more e-mail.

Claudia

CLAUDIA CHRISTIAN | Senior Vice President, Global Clinical Operations

T: (b)(6) **M:** (b)(6) | (b)(6) fhiclinical.com

359 Blackwell Street, Suite 200, Durham, NC 27701

<image011.png> <image003.png> <image004.png>





- Site assessed in 3rd round
- Site assessed in 2nd round
- Site assessed in 1st round



